Circadian rhythm in immunotherapy and cellular therapy: impacts on the tumor microenvironment.

Acta Biochim Biophys Sin (Shanghai) · 2026 · PMC12862608 · PMID 41261920

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

In an ICB phase III trial, pembrolizumab, an immune checkpoint inhibitor drug, combined with concurrent chemoradiotherapy (CCRT) followed by maintenance pembrolizumab significantly improved progression-free survival (PFS) and demonstrated a positive trend in OS compared with CCRT with placebo in patients with newly diagnosed, high-risk, locally advanced cervical cancer [88] .

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.